• 1
    Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003;4(suppl 2):S25S38.
  • 2
    Dodrill CB. Neuropsychological effects of seizures. Epilepsy Behav 2004;5(suppl 1):S21S24.
  • 3
    Rhea R. New oral antiepileptic agents. Cleve Clin Med Ed 2001;4. Available at Accessed March 17, 2006.
  • 4
    Weatherly G, Carlson BE, Risse GL, et al. Cognitive task performance of patients taking zonisamide: the Minnesota Epilepsy Group. 2003. Available at:
  • 5
    Fisher RS, Vickrey BG, Gibson P, et al. The impact of epilepsy from the patient's perspective II: views about therapy and health care. Epilepsy Res 2000;41:5361.
  • 6
    Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004;3:618621.
  • 7
    Fink-Jensen A, Suzdak PD, Swedberg MDB, et al. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992;220:197201.
  • 8
    Borden LA. GABA transporter heterogeneity: pharmacology and cellular localization. Neurochem Int 1996;29:335356.
  • 9
    Leach JP, Brodie MJ. Tiagabine. Lancet 1998;351:203207.
  • 10
    Crawford P, Meinardi H, Brown S, et al. Tiagabine: efficacy and safety in adjunctive treatment of partial seizures. Epilepsia 2001;42:531538.
  • 11
    Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998;55:5662.
  • 12
    Kälviäinen R, Brodie MJ, Duncan J, et al. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures: Northern European Tiagabine Study Group. Epilepsy Res 1998;30:3140.
  • 13
    Sachdeo RC, Leroy RF, Krauss GJ, et al. Tiagabine therapy for complex partial seizures. a dose-frequency study. the tiagabine study group. Arch Neurol 1997;54:595601.
  • 14
    Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:3742.
  • 15
    Sveinbjornsdottir S, Sander JW, Patsalos PN, et al. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3:2935.
  • 16
    Kälviäinen R, Äikiä M, Mervaala E, et al. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996;25:291297.
  • 17
    Dodrill CB, Arnett JL, Sommerville KW, et al. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:10251031.
  • 18
    Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6:373381.
  • 19
    Dodrill CB, Arnett JL, Deaton R, et al. Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood. Epilepsy Res 2000;42:123132.
  • 20
    Äikiä M, Kälviäinen R, Salmenperä T, et al. Cognitive effects of tiagabine monotherapy. Epilepsia 1997;38:107.
  • 21
    Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998;39:3342.
  • 22
    Engelberts NH, Klein M, Van Der Ploeg HM, et al. Cognition and health-related quality of life in chronic well-controlled patients with partial epilepsy on carbamazepine monotherapy. Epilepsy Behav 2002;3:316321.
  • 23
    Prevey ML, Delaney RC, Cramer JA, et al. Effects of valproate on cognitive functioning. comparison with carbamazepine. the Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996;53:10081016.
  • 24
    Drane DL, Meador KJ. Epilepsy, anticonvulsant drugs and cognition. Baillieres Clin Neurol 1996;5:877885.
  • 25
    Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995;36(suppl 2):S46S65.
  • 26
    Genton P, Guerrini R, Perucca E. Tiagabine in clinical practice. Epilepsia 2001;42(suppl 3):4245.
  • 27
    Wechsler D. Wechsler Adult Intelligence Scale—Revised. San Antonio , Texas : The Psychological Corporation, 1981.
  • 28
    Lezak MD. Neuropsychological assessment. 3rd ed. New York : Oxford University Press, 1995.
  • 29
    Wechsler DA. A standardized memory scale for clinical use. J Psychol 1945;19:8795.
  • 30
    Reitan RM. The validity of the Trail-Making Test as an indicator of organic brain damage. Percept Mot Skill 1958;8:271276.
  • 31
    Allison RS. Perseveration as a sign of diffuse and focal brain damage. BMJ 1966;2:10271032.
  • 32
    Alpherts WCJ, Aldenkamp AJ. Computerized neuropsychological assessment of cognitive functioning in children with epilepsy. Epilepsia 1990;31:S35S40.
  • 33
    Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive and behavioral effects of carbamazepine and phenytoin in healthy adults. Neurology 1991;41:15371540.
  • 34
    Meador KJ, Loring DW, Ray PG, et al. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Neurology 2001;56:11771182.
  • 35
    Meador KJ, Loring DW, Ray PG, et al. Differential cognitive effects of carbamazepine and gabapentin. Epilepsia 1999;40:12791285.
  • 36
    Imperiale TF. Meta-analysis: when and how. Hepatology 1999;29:26S-31S.
  • 37
    Ioannidis JP, Lau J. Pooling research results: benefits and limitations of meta-analysis. Jt Comm J Qual Improv 1999;25:462469.
  • 38
    Kälviäinen R, Äikiä M, Saukkonen AM, et al. Vigabatrin versus carbamazepine monotherapy in newly diagnosed epilepsy, a randomized controlled study. Arch Neurol 1995;52:989996.
  • 39
    Dikmen SS, Heaton RK, Grant I, et al. Test-retest reliability and practice effects of expanded Halstead-Reitan Neuropsychological Test Battery. J Int Neuropsychol Soc 1999;5:346356.
  • 40
    Kälviäinen R. Cognitive effects of GABAergic antiepileptic drugs. Electroencephalogr Clin Neurophysiol 1999;50:458464.